Several studies of breast cancer suggest that PIK3CA mutations are more frequent in estrogen receptor-alpha- positive (ERα+) breast tumors (30% to 40%) than in receptor-alpha-negative (ERα-) breast tumors (10% to 20%) [3,7,10,11]. This evidence concerns the gene ESR1 and breast carcinoma.